MedTrace Logo

Panuri Performance Study

NCT07587866 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2026-05-14

No results posted yet for this study

Summary

The main purpose of the study is to assess the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma (PDAC) the most common type of pancreatic cancer that accounts for approximately 90% of all pancreatic cancer cases.

The study aims to characterize the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma in patients with symptoms supporting a clinical suspicion of pancreatic cancer The Panuri test is intended for professional laboratory use for diagnostic purposes.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DIAGNOSTIC_TEST

Panuri test

In vitro diagnostic assay designed to detect, in human urine samples pancreatic ductal adenocarcinoma

Sponsors & Collaborators

  • Urteste S.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • Hungary
  • Italy
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07587866 on ClinicalTrials.gov